Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol
Hydroxytyrosol as an Endogenous and Natural Antioxidant: Modulation by Alcohol Intake. Substudy 1. Evaluating the Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol (DOPET).
1 other identifier
interventional
24
1 country
1
Brief Summary
Health benefits for humans derived from low dose intake of ethanol could partially be explained by its interaction with dopamine (DA) oxidative metabolism. Ethanol is expected to induce an increase in the formation of a DA minor metabolite: DOPET (hydroxytyrosol). Hydroxytyrosol is one of the most potent antioxidants present in Mediterranean Diet. The study is aimed at establishing the contribution of ethanol on hydroxytyrosol formation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started May 2009
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2010
CompletedFirst Submitted
Initial submission to the registry
February 5, 2013
CompletedFirst Posted
Study publicly available on registry
February 11, 2013
CompletedFebruary 11, 2013
February 1, 2013
1.1 years
February 5, 2013
February 7, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Hydroxytyrosol biological fluids concentrations
Hydroxytyrosol concentrations in plasma and urine
0-24h after administration
Secondary Outcomes (5)
Subjective drunkenness
0-6h after administration
Vital signs
0-6h after administration
Ethanol concentration
0-6h after administration
Ethanol metabolites concentrations
0-24h after administration
Dopamine metabolites concentrations
0-24h after administration
Study Arms (3)
Water
PLACEBO COMPARATORLemon-flavoured water (150 ml)
Ethanol high dose
ACTIVE COMPARATORThe high dose corresponds to 30 g of ethanol in pilot cohort 1, to 12 g of ethanol in pilot cohort 2 and to 42 g of ethanol in pilot cohort 3. For the definitive study the high dose corresponds to 30 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
Ethanol low dose
ACTIVE COMPARATORThe low dose corresponds to 18 g of ethanol in pilot cohort 1, to 6 g of ethanol in pilot cohort 2 and to 24 g of ethanol in pilot cohort 3. For the definitive study the low dose corresponds to 18 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
Interventions
Eligibility Criteria
You may qualify if:
- Clinical history and physical examination demonstrating no organic or psychiatric disorders.
- The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
- The body mass index (BMI=weigh/height2) will range from 19 to 27 kg/m2, and the weight from 50 to 110 kg.
- Understanding and accepting the study procedures and signing the informed consent.
You may not qualify if:
- History or clinical evidence of alcoholism, drug abuse, or regular use of psychoactive drugs.
- Having suffered any organic disease or major surgery in the three months prior to the study start.
- History of psychiatric disorders.
- Smokers of more than 20 cigarettes per day.
- Taking more than 30 g of alcohol a day
- Blood donation 8 weeks before or participation in other clinical trials with drugs in the previous 12 weeks.
- Subjects with intolerance or adverse reactions to ethanol
- History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
- Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
- Subjects with positive serology to Hepatitis B, C or HIV.
- To be eligible, the subjects must agree to follow a diet free from ethanol and olive oil in the 72 hours prior to the start of each session and until the end of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Parc de Salut Marlead
- Fundacion IMIMcollaborator
Study Sites (1)
Parc de Salut Mar
Barcelona, Barcelona, 08003, Spain
Related Publications (1)
Perez-Mana C, Farre M, Pujadas M, Mustata C, Menoyo E, Pastor A, Langohr K, de la Torre R. Ethanol induces hydroxytyrosol formation in humans. Pharmacol Res. 2015 May-Jun;95-96:27-33. doi: 10.1016/j.phrs.2015.02.008. Epub 2015 Mar 20.
PMID: 25801942DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Magí Farré, MD, PhD
Parc de Salut Mar
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 5, 2013
First Posted
February 11, 2013
Study Start
May 1, 2009
Primary Completion
June 1, 2010
Study Completion
June 1, 2010
Last Updated
February 11, 2013
Record last verified: 2013-02